This explains the rationale and success of inhaled treprostinil observed in the INCREASE study; in that trial, inhaled treprostinil significantly improved exercise capacity, reduced NT-proBNP levels, lowered the risk of clinical worsening, and decreased lung disease exacerbations during the 16-week study, also, of importance, there was no observed decline in lung function [14]. This evidence concerns the gene NPPB and lung disorder.